Following adults with CIDP who start treatment with efgartigimod in everyday care
Observes how efgartigimod works in adults with CIDP in routine care.
Plain-language title generated from the registry record
Registry title: Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
Key facts
- Where
- Wilmington, United StatesSee the site
Where in United States
- PPD VirtualWilmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- argenx
- Trial code
- NCT07264426
- Record updated
- 3 November 2026
- Original description
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.Read full original descriptionShow less
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.
As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.
Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
Inclusion: Aged ≥18 years at time of providing informed consent; Diagnosed with CIDP; Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country; Efgartigimod treatment-naïve at time of screening.
Exclusion: Polyradiculoneuropathy due to any other cause(s); Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod.